Serum Thyroglobulin as a Tumor Marker in Thyroid Cancer
Author Information
Author(s): S.0. Thoresen, O. Myking, E. Glattre, K. Rootwelt, A. Andersen, O.P. Foss
Primary Institution: The Cancer Registry of Norway
Hypothesis
Does serum thyroglobulin (S-Tg) serve as a preclinical tumor marker for thyroid cancer?
Conclusion
The study found that elevated S-Tg levels can occur years before the clinical diagnosis of thyroid cancer.
Supporting Evidence
- 12 of 43 patients had S-Tg values greater than 150 pg/l compared to only 3 out of 128 controls.
- The relative risk of thyroid cancer increases with higher S-Tg levels.
- Statistically significant differences in S-Tg levels were found between cases and controls.
Takeaway
Doctors can check a blood test for a substance called thyroglobulin to see if someone might have thyroid cancer even before they feel sick.
Methodology
A case-control study comparing S-Tg levels in 43 thyroid cancer patients with 128 matched healthy controls.
Limitations
The study may have included controls with benign thyroid diseases, which could affect the results.
Participant Demographics
43 patients (13 males, 30 females) with thyroid cancer and 128 matched healthy controls.
Statistical Information
P-Value
<0.0005
Statistical Significance
p<0.0005
Want to read the original?
Access the complete publication on the publisher's website